BACKGROUND: Despite recent insights into its aetiology, hidradenitis suppurativa (HS) remains an intractable and debilitating condition for its sufferers, affecting an estimated 2% of the population. It is characterized by chronic, relapsing abscesses, with accompanying fistula formation within the apocrine glandbearing skin, such as the axillae, ano-genital areas and breasts. Standard treatments remain ineffectual and the disease often runs a chronic relapsing course associated with significant psychosocial trauma for its sufferers. OBJECTIVE: To evaluate the clinical efficacy of Metformin in treating cases of HS which have not responded to standard therapies. METHODS: Twenty-five patients were treated with Metformin over a period of 24 weeks. Clinical severity of the disease was assessed at time 0, then after 12 weeks and finally after 24 weeks. Results were evaluated using Sartorius and DLQI scores. RESULTS: Eighteen patients clinically improved with a significant average reduction in their Sartorius score of 12.7 and number of monthly work days lost reduced from 1.5 to 0.4. Dermatology life quality index (DLQI) also showed a significant improvement in 16 cases, with a drop in DLQI score of 7.6. CONCLUSION: Metformin helps control HS with minimal side effects and good patient compliance and can represent a further agent in the spectrum of treatments available in the treatment of this disease.
BACKGROUND: Despite recent insights into its aetiology, hidradenitis suppurativa (HS) remains an intractable and debilitating condition for its sufferers, affecting an estimated 2% of the population. It is characterized by chronic, relapsing abscesses, with accompanying fistula formation within the apocrine glandbearing skin, such as the axillae, ano-genital areas and breasts. Standard treatments remain ineffectual and the disease often runs a chronic relapsing course associated with significant psychosocial trauma for its sufferers. OBJECTIVE: To evaluate the clinical efficacy of Metformin in treating cases of HS which have not responded to standard therapies. METHODS: Twenty-five patients were treated with Metformin over a period of 24 weeks. Clinical severity of the disease was assessed at time 0, then after 12 weeks and finally after 24 weeks. Results were evaluated using Sartorius and DLQI scores. RESULTS: Eighteen patients clinically improved with a significant average reduction in their Sartorius score of 12.7 and number of monthly work days lost reduced from 1.5 to 0.4. Dermatology life quality index (DLQI) also showed a significant improvement in 16 cases, with a drop in DLQI score of 7.6. CONCLUSION:Metformin helps control HS with minimal side effects and good patient compliance and can represent a further agent in the spectrum of treatments available in the treatment of this disease.
Authors: Puneet Agarwal; Snehal Balvant Lunge; Nandini Sundar Shetty; Priyanka Karagaiah; Steven Daveluy; Alex G Ortega-Loayza; Thrasyvoulos Tzellos; Jacek C Szepietowski; Christos C Zouboulis; Stephan Grabbe; Mohamad Goldust Journal: J Clin Med Date: 2022-06-30 Impact factor: 4.964
Authors: Mahendra Pratap Kashyap; Jasim Khan; Rajesh Sinha; Lin Jin; Venkatram Atigadda; Jessy S Deshane; Ayesha R Ahmed; Ali Kilic; Chander Raman; M Shahid Mukhtar; Craig A Elmets; Mohammad Athar Journal: Semin Cell Dev Biol Date: 2022-02-04 Impact factor: 7.499
Authors: Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin Journal: J Am Acad Dermatol Date: 2019-03-11 Impact factor: 15.487